A detailed history of Massachusetts Financial Services CO transactions in Bio Atla, Inc. stock. As of the latest transaction made, Massachusetts Financial Services CO holds 526,462 shares of BCAB stock, worth $721,252. This represents 0.0% of its overall portfolio holdings.

Number of Shares
526,462
Previous 529,156 0.51%
Holding current value
$721,252
Previous $1.3 Million 39.2%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$1.88 - $3.46 $5,064 - $9,321
-2,694 Reduced 0.51%
526,462 $1.81 Million
Q4 2023

Feb 08, 2024

BUY
$1.27 - $3.18 $621 - $1,555
489 Added 0.09%
529,156 $1.3 Million
Q3 2023

Nov 08, 2023

SELL
$1.7 - $3.07 $387,066 - $698,996
-227,686 Reduced 30.1%
528,667 $898,000
Q2 2023

Aug 09, 2023

SELL
$2.83 - $3.87 $30,363 - $41,521
-10,729 Reduced 1.4%
756,353 $2.27 Million
Q1 2023

May 10, 2023

BUY
$2.3 - $8.25 $254,839 - $914,100
110,800 Added 16.88%
767,082 $2.06 Million
Q4 2022

Feb 13, 2023

BUY
$7.63 - $11.01 $949,896 - $1.37 Million
124,495 Added 23.41%
656,282 $5.41 Million
Q3 2022

Nov 09, 2022

BUY
$2.94 - $11.87 $105,895 - $427,545
36,019 Added 7.27%
531,787 $4.1 Million
Q2 2022

Aug 09, 2022

SELL
$2.13 - $5.38 $7,929 - $20,029
-3,723 Reduced 0.75%
495,768 $1.41 Million
Q1 2022

May 11, 2022

BUY
$4.38 - $18.78 $60,448 - $259,182
13,801 Added 2.84%
499,491 $2.5 Million
Q4 2021

Feb 10, 2022

SELL
$19.0 - $30.95 $67,925 - $110,646
-3,575 Reduced 0.73%
485,690 $9.53 Million
Q3 2021

Nov 10, 2021

BUY
$29.44 - $43.74 $1.95 Million - $2.9 Million
66,242 Added 15.66%
489,265 $14.4 Million
Q2 2021

Aug 13, 2021

SELL
$38.07 - $56.17 $46,216 - $68,190
-1,214 Reduced 0.29%
423,023 $17.9 Million
Q1 2021

May 13, 2021

SELL
$32.41 - $70.91 $2.45 Million - $5.36 Million
-75,634 Reduced 15.13%
424,237 $21.6 Million
Q4 2020

Feb 12, 2021

BUY
$31.02 - $35.16 $15.5 Million - $17.6 Million
499,871 New
499,871 $17 Million

Others Institutions Holding BCAB

About BioAtla, Inc.


  • Ticker BCAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,304,100
  • Market Cap $49.7M
  • Description
  • BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...
More about BCAB
Track This Portfolio

Track Massachusetts Financial Services CO Portfolio

Follow Massachusetts Financial Services CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Massachusetts Financial Services CO , based on Form 13F filings with the SEC.

News

Stay updated on Massachusetts Financial Services CO with notifications on news.